Evolving Treatment Strategies in Chronic Lymphocytic Leukemia: Insights From ASH 2023

Richard Furman, MD, and Chaitra S. Ujjani, MD, discuss the changing landscape of treatment strategies for patients with CLL, highlighting key updates presented at ASH 2023 and their potential implication on clinical practice.

EP. 1: Navigating Frontline Treatment Options in CLL

December 21st 2023

Chaitra S. Ujjani, MD, provides an overview of the frontline treatment landscape for CLL, highlighting key data and clinical factors to guide treatment selection.

EP. 2: Updates from SEQUOIA and ELEVATE-TN: Impact on CLL Treatment Selection in the First-Line Setting

January 4th 2024

Chaitra S. Ujjani, MD, examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.

EP. 3: Expert Perspectives on Extended Follow-Up Data from ALPINE

January 11th 2024

Chaitra S. Ujjani, MD examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.

EP. 4: Insights from ELEVATE-RR and Considerations for Combination Therapy in R/R CLL

January 18th 2024

Oncology experts discuss findings from ELEVATE-RR and outline key considerations for combination therapy with acalabrutinib plus obinutuzumab.

EP. 5: Navigating Therapy Options in R/R CLL: Consideration Factors for Treatment Selection

January 25th 2024

Faculty offer expert guidance regarding treatment selection for patients with R/R CLL, highlighting parallels with frontline considerations.

EP. 6: Treatment Strategies for Managing BTK Inhibitor Intolerance in CLL

February 1st 2024

Richard Furman, MD, outlines his strategy for addressing BTK inhibitor intolerance in CLL patients, underscoring the significance of BTK inhibitors in CLL treatment and advocating for transitioning to an alternative BTK inhibitor rather than completely discontinuing the class in cases of drug intolerance.

EP. 7: Expert Perspectives on Emerging Data Surrounding BTK Inhibitor Resistance in CLL

February 8th 2024

Faculty offer expert insights into emerging data on BTK inhibitor resistance in CLL, referencing earlier findings that indicate the potential existence of mutations before BTK inhibitor exposure and the process of clonal selection.